Phaseline

Companies › SAPU NANO (US)

SAPU NANO (US): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sapu003
mTOR inhibitor
MTORPhase 1Breast Cancer MetastaticDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07369505Sapu003Phase 1Breast Cancer MetastaticOncologyDec 2026

Targets

MTOR (1)

Companies with the same targets

iVascular S.L.U. Restorbio Faeth Therapeutics Celcuity Palvella Therapeutics Supernus Pharmaceuticals Eli Lilly AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.